These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28970039)

  • 1. Clinical conundrums in antithrombotic therapy management: A Delphi Consensus panel.
    Colonna P; Andreotti F; Ageno W; Pengo V; Marchionni N
    Int J Cardiol; 2017 Dec; 249():249-256. PubMed ID: 28970039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of antithrombotic therapy in gray areas of venous thromboembolism: a Delphi consensus panel.
    Barillari G; Bortoluzzi C; Giorgi M; Orabona R; Pacetti E; Sciatti E; Zaffaroni M; Dentali F
    Intern Emerg Med; 2020 Oct; 15(7):1255-1264. PubMed ID: 32232785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivaroxaban: an oral factor Xa inhibitor.
    Thomas TF; Ganetsky V; Spinler SA
    Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. State of play and future direction with NOACs: An expert consensus.
    Cohen AT; Lip GY; De Caterina R; Heidbuchel H; Zamorano JL; Agnelli G; Verheugt F; Camm AJ
    Vascul Pharmacol; 2018 Jul; 106():9-21. PubMed ID: 29656119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study.
    Taillandier S; Olesen JB; Clémenty N; Lagrenade I; Babuty D; Lip GY; Fauchier L
    J Cardiovasc Electrophysiol; 2012 Jul; 23(7):708-13. PubMed ID: 22268375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Data from a multidisciplinary poll of 178 expert physicians on the usage of non-vitamin K Oral Anticoagulants in patients with atrial fibrillation and venous thromboembolism.
    Colonna P; Andreotti F; Ageno W; Pengo V; Marchionni N
    Data Brief; 2017 Dec; 15():532-539. PubMed ID: 29071290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
    Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
    Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antithrombotic therapy for patients with an indication for oral anticoagulation undergoing percutaneous coronary intervention with stent: The case of venous thromboembolism.
    Riva L; Ageno W; Di Pasquale G; Agnelli G; Rubboli A
    Int J Cardiol; 2018 Oct; 269():75-79. PubMed ID: 30060974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral contraception and menstrual bleeding during treatment of venous thromboembolism: Expert opinion versus current practice: Combined results of a systematic review, expert panel opinion and an international survey.
    Klok FA; Schreiber K; Stach K; Ageno W; Middeldorp S; Eichinger S; Delluc A; Blondon M; Ay C
    Thromb Res; 2017 May; 153():101-107. PubMed ID: 28376343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry.
    Lip GY; Laroche C; Popescu MI; Rasmussen LH; Vitali-Serdoz L; Dan GA; Kalarus Z; Crijns HJ; Oliveira MM; Tavazzi L; Maggioni AP; Boriani G
    Europace; 2015 Dec; 17(12):1777-86. PubMed ID: 26321406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.
    Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Ioachim PM; Tica O; Boriani G; Cimaglia P; Diemberger I; Hellum CF; Mortensen B; Maggioni AP
    Am J Med; 2014 Jun; 127(6):519-29.e1. PubMed ID: 24486284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment and Mitigation of Bleeding Risk in Atrial Fibrillation and Venous Thromboembolism: Executive Summary of a European and Asia-Pacific Expert Consensus Paper.
    Gorog DA; Gue YX; Chao TF; Fauchier L; Ferreiro JL; Huber K; Konstantinidis SV; Lane DA; Marin F; Oldgren J; Potpara T; Roldan V; Rubboli A; Sibbing D; Tse HF; Vilahur G; Lip GYH
    Thromb Haemost; 2022 Oct; 122(10):1625-1652. PubMed ID: 35793691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial.
    Kirchhof P; Blank BF; Calvert M; Camm AJ; Chlouverakis G; Diener HC; Goette A; Huening A; Lip GYH; Simantirakis E; Vardas P
    Am Heart J; 2017 Aug; 190():12-18. PubMed ID: 28760205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
    Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
    Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
    Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atrial fibrillation and risk of venous thromboembolism: a Swedish Nationwide Registry Study.
    Hornestam B; Adiels M; Wai Giang K; Hansson PO; Björck L; Rosengren A
    Europace; 2021 Dec; 23(12):1913-1921. PubMed ID: 34279622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apixaban in the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation.
    Pujadas-Mestres L; Escolar G; Arellano-Rodrigo E; Galán AM
    Drugs Today (Barc); 2013 Jul; 49(7):425-36. PubMed ID: 23914351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry.
    Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Oliveira MM; Mairesse G; Crijns HJ; Simantirakis E; Atar D; Kirchhof P; Vardas P; Tavazzi L; Maggioni AP
    Europace; 2014 Mar; 16(3):308-19. PubMed ID: 24351881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.
    Camm AJ; Accetta G; Ambrosio G; Atar D; Bassand JP; Berge E; Cools F; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Kayani G; Koretsune Y; Mantovani LG; Misselwitz F; Oh S; Turpie AG; Verheugt FW; Kakkar AK;
    Heart; 2017 Feb; 103(4):307-314. PubMed ID: 27647168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulation in "real world" patients with atrial fibrillation in Italy: results from the ISPAF (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study.
    Volterrani M; Iellamo F; Rosano G; Guarini P; Pusineri E; Bonassi S; Chimini C; Zaccà F; Proto C;
    Int J Cardiol; 2013 Oct; 168(5):4729-33. PubMed ID: 23948115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.